Anzeige
Mehr »
Login
Dienstag, 11.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E27P | ISIN: CA30053H1055 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
EVOME MEDICAL TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
EVOME MEDICAL TECHNOLOGIES INC 5-Tage-Chart

Aktueller Chart EVOME MEDICAL TECHNOLOGIES Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
EVOME MEDICAL TECHNOLOGIES INC-Investoren interessieren sich auch für diese Wertpapiere
PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA GuidanceSAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative...
► Artikel lesen
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate CancerA Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in...
► Artikel lesen
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS Robotic System, the Next-Generation, AI-Powered Platform for Aquablation TherapySAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative...
► Artikel lesen
GeneDx Announces Preliminary 2024 Financial ResultsSTAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for...
► Artikel lesen
GeneDx Reports Third Quarter 2024 Financial Results and Business HighlightsSTAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third...
► Artikel lesen
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 ResultsFRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary...
► Artikel lesen